Determinants of Multidrug-Resistant Mycobacterium tuberculosis Infection: A Multicenter Study from Southern Ethiopia
Abdulkerim Badgeba,Mulugeta Shegaze Shimbre,Mathewos Alemu Gebremichael,Biruk Bogale,Menur Berhanu,Hanan Abdulkadir
DOI: https://doi.org/10.2147/IDR.S363628
2022-07-05
Infection and Drug Resistance
Abstract:Abdulkerim Badgeba, 1 Mulugeta Shegaze Shimbre, 2 Mathewos Alemu Gebremichael, 3 Biruk Bogale, 4 Menur Berhanu, 5 Hanan Abdulkadir 6 1 Department of Public Health, College of Medicine and Health Sciences, Werabe University, Werabe, Ethiopia; 2 School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China; 3 Department of Public Health, College of Health Sciences, Bonga University, Bonga, Ethiopia; 4 School of Public Health, College of Medicine and Health Sciences, Mizan Tepi University, Mizan Aman, Ethiopia; 5 Ohio State University Global One-Health Initiatives, Arba Minch, Ethiopia; 6 Department of Reproductive Health, School of Public Health, College of Medicine and Health Sciences, Arba Minch University, Arba Minch, Ethiopia Correspondence: Mathewos Alemu Gebremichael; Biruk Bogale, Email ; Background: Multidrug-resistant tuberculosis (MDR-TB) continues to be a public health problem. Globally in 2019, a total of 465,000 people developed rifampicin-resistant TB (RR-TB), of which 78% had MDR-TB. There is a paucity of evidence on the determinants of MDR-TB in southern Ethiopia. Hence, this study aimed to assess the determinants of MDR-TB in southern Ethiopia. Methods: A hospital-based case–control study was conducted in southern Ethiopia. The cases were all MDR-TB patients attending TB clinics, and controls were all patients who were declared as cured or treatment completed. The cases were selected by consecutive sampling, and a simple random sampling technique was used for controls. Multivariable logistic regression analysis was done to identify determinants of MDR-TB. Adjusted odds ratios (AORs) with 95% confidence intervals (CIs) were computed, and statistical significance was declared at a P-value less than 5%. Results: A total of 191 participants, 67 cases, and 124 controls were included. TB patients facing social stigma (AOR = 8.9, 95% CI: 2.3– 34.6), living in a household with one room (AOR = 12.3, 95% CI: 2.3– 63.5), and two rooms (AOR = 9.7, 95% CI: 1.7– 54.8), having the previous history of TB treatment (AOR = 11.8, 95% CI: 2.9– 47), having baseline body mass index (BMI) less than 18.5Kg/m 2 (AOR = 4.5, 95% CI: 1.2– 16.8), and having pulmonary TB (AOR = 5.1, 95% CI: 1.33– 19.8) were determinants of MDR-TB. Conclusion: In this study, TB patients facing social stigma, living in one- and two-roomed houses, having a previous history of TB treatment, having low baseline BMI and pulmonary type of TB had higher odds of MDR-TB. Therefore, health workers in TB control programs should include mental health services in the TB care protocol, and priority should be given to malnutrition screening as a first-line diagnosis, nutritional supplements, and health education about proper housing. Keywords: multidrug-resistant tuberculosis, determinants, case-control, southern Ethiopia Tuberculosis (TB) remains one of the major causes of morbidity, and the leading cause of death from a single infectious agent and ranking above Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS). 1,2 TB is caused by the Mycobacterium tuberculosis complex and other closely related species like Mycobacterium bovis and Mycobacterium africanum . The bacilli spread like tiny particles (droplet nuclei with 1–5 microns in diameter) expelled by the person with infectious pulmonary or laryngeal TB disease. 1,2 Drug-Resistant TB (DR-TB) is resistant to one of the four first-line antibiotic drugs used to treat TB. The most common is isoniazid-resistant TB. Multidrug-resistant TB (MDR-TB) is caused by an organism that is resistant to at least an isoniazid and rifampin, the two most potent TB drugs that are used to treat all persons with TB disease. 2,3 Extensively drug-resistant tuberculosis (XDR-TB) is a subset of MDR-TB with additional resistance to any fluoroquinolone (ie Levofloxacin or Moxifloxacin) and at least one of the three injectable second-line drugs (ie, amikacin, kanamycin, or capreomycin). 2,3 TB and DR-TB continue to be public health problems. Globally in 2019, about 10 million people developed TB and 1.4 million died, and around 465,000 people developed rifampicin-resistant TB (RR-TB), of which 78% had MDR-TB. 1 Among these 3.3% of new TB cases and 18% of previously treated cases had MDR/RR-TB. Similarly, there were estimated 182,000 deaths from MDR/RR-TB. About 49% of the global burden sharing MDR-TB cases are estimated to occur in India (27%), China (14%), and the Russian Federation (8%). 1 The 2020 World Health Organization (WHO) global tuberculosis report sugge -Abstract Truncated-
pharmacology & pharmacy,infectious diseases